June 15, 2017 | Israeli bio-pharmaceutical company Eloxx has raised $24 million from Catalyst CEL Fund, Israeli venture capital fund for life sciences Pontifax, and others. The company develops treatments for patients with rare genetic diseases triggered by mutations like Cystic Fibrosis and Cystinosis. Founded in 2013 by Dr. Silvia Noiman, Eloxx recently merged with Sevion Therapeutics and became a Sevion subsidiary. Sevion will use the name Eloxx and attempt to list its shares on Nasdaq. [Photo: GeneG]
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments